**WHAT IS CLAIMED IS:**

1. Use of verinurad or a pharmaceutically acceptable salt thereof, a xanthine oxidase inhibitor, and dapagliflozin in the manufacture of a medicament for a combination therapy for reducing serum uric acid levels in a subject in need thereof, wherein the medicament is to be administered to the subject.

2. Use of verinurad or a pharmaceutically acceptable salt thereof, a xanthine oxidase inhibitor, and dapagliflozin in the manufacture of a medicament for a combination therapy for treating or preventing ~~a condition associated with~~ hyperuricemia in a subject in need thereof, wherein the medicament is to be administered to the subject.

3. Use of verinurad or a pharmaceutically acceptable salt thereof, a xanthine oxidase inhibitor, and dapagliflozin in the manufacture of a medicament for a combination therapy for treating or preventing ~~The use of claim 2, wherein the condition is~~ gout, a recurrent gout attack, gouty arthritis, hypertension, ~~a cardiovascular disease, coronary heart disease, heart failure,~~ Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, chronic kidney disease, kidney stones, kidney failure, diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof in a subject in need thereof.

4. The use of claim 2, wherein the condition is gout.

5. The use of claim 2, wherein the condition is chronic kidney disease.

~~6. The use of claim 2, wherein the condition is heart failure.~~

6~~7~~. The use of any one of claims 1 – 5~~6~~, wherein the xanthine oxidase inhibitor is febuxostat or a pharmaceutically acceptable salt thereof.

7~~8~~. The use of any one of claims 1 – 5~~6~~, wherein the xanthine oxidase inhibitor is allopurinol or a pharmaceutically acceptable salt thereof.

8~~9~~. Use of verinurad or a pharmaceutically acceptable salt thereof, allopurinol or a pharmaceutically acceptable salt thereof, and dapagliflozin in the manufacture of a medicament for a combination therapy for treating or preventing chronic kidney disease in a subject in need thereof, wherein the medicament is to be administered to the subject.

~~10. Use of verinurad or a pharmaceutically acceptable salt thereof, allopurinol or a pharmaceutically acceptable salt thereof, and dapagliflozin in the manufacture of a~~

~~medicament for treating or preventing heart failure in a subject in need thereof, wherein the medicament is to be administered to the subject.~~

9~~11~~. Use of verinurad or a pharmaceutically acceptable salt thereof, and a xanthine oxidase inhibitor in the manufacture of a medicament for a combination therapy for reducing serum uric acid levels in a subject who is currently being treated with dapagliflozin, wherein the medicament is to be administered to the subject.

10~~12~~. The use of claim 9~~11~~, wherein the subject has diabetes mellitus.

11~~13~~. The use of claim 9~~11~~ or 10~~12~~, wherein the xanthine oxidase inhibitor is febuxostat or a pharmaceutically acceptable salt thereof.

12~~14~~. The use of claim 9~~11~~ or 10~~12~~, wherein the xanthine oxidase inhibitor is allopurinol or a pharmaceutically acceptable salt thereof.

13~~15~~. Use of verinurad or a pharmaceutically acceptable salt thereof, and a xanthine oxidase inhibitor in the manufacture of a medicament for a combination therapy for treating or preventing ~~a condition associated with~~ hyperuricemia in a subject who is currently being treated with dapagliflozin, wherein the medicament s to be administered to the subject.

14~~16~~. The use of claim 13~~15~~, wherein the subject has diabetes mellitus.

15~~17~~. Use of verinurad or a pharmaceutically acceptable salt thereof, and a xanthine oxidase inhibitor in the manufacture of a medicament for a combination therapy for treating or preventing ~~The use of claim 15, wherein the condition is~~ gout, a recurrent gout attack, gouty arthritis, hypertension, ~~a cardiovascular disease, coronary heart disease, heart failure,~~ Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, chronic kidney disease, kidney stones, kidney failure, diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof in a subject who is currently being treated with dapagliflozin.

16~~18~~. Use of verinurad or a pharmaceutically acceptable salt thereof, and a xanthine oxidase inhibitor in the manufacture of a medicament for a combination therapy for treating or preventing ~~The use of claim 16, wherein the condition is~~ gout, a recurrent gout attack, gouty arthritis, hypertension, a cardiovascular disease, coronary heart disease, heart failure, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, chronic kidney disease, kidney stones, kidney failure, diabetic kidney disease, joint inflammation,

arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof in a subject who is currently being treated with dapagliflozin, wherein the subject has diabetes mellitus.

17~~19~~. The use of claim 13~~15~~, wherein the condition is gout.

18~~20~~. The use of claim 14~~16~~, wherein the condition is gout.

19~~21~~. The use of claim 13~~15~~, wherein the condition is chronic kidney disease.

20~~22~~. The use of claim 14~~16~~, wherein the condition is chronic kidney disease.

~~23. The use of claim 15, wherein the condition is heart failure.~~

21~~24~~. The use of claim 16, wherein the condition is heart failure.

22~~25~~. The use of any one of claims 13~~15~~ – 21~~24~~, wherein the xanthine oxidase inhibitor is febuxostat or a pharmaceutically acceptable salt thereof.

23~~26~~. The use of any one of claims 13~~15~~ – 21~~24~~, wherein the xanthine oxidase inhibitor is allopurinol or a pharmaceutically acceptable salt thereof.

24~~27~~. Use of verinurad or a pharmaceutically acceptable salt thereof, and allopurinol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing chronic kidney disease in a subject with diabetes mellitus who is currently being treated with dapagliflozin, wherein the medicament is to be administered to the subject.

25~~28~~. Use of verinurad or a pharmaceutically acceptable salt thereof, and allopurinol or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing heart failure in a subject with diabetes mellitus who is currently being treated with dapagliflozin, wherein the medicament is to be administered to the subject.

26~~29~~. A pharmaceutical composition comprising:

verinurad or a pharmaceutically acceptable salt thereof;

a xanthine oxidase inhibitor;

dapagliflozin; and

a pharmaceutically acceptable excipient or carrier.

27~~30~~. The pharmaceutical composition of claim 26~~29~~, wherein the xanthine oxidase inhibitor is febuxostat, or a pharmaceutically acceptable salt thereof.

28~~31~~. The pharmaceutical composition of claim 26~~29~~, wherein the xanthine oxidase inhibitor is allopurinol, or a pharmaceutically acceptable salt thereof.

29~~32~~. Use of the pharmaceutical composition of any one of claims 26~~29~~ – 28~~31~~ in the manufacture of a medicament for reducing serum uric acid levels in a subject in need thereof, wherein an effective amount of the medicament is to be administered~~-~~ to the subject.

30~~33~~. Use of the pharmaceutical composition of any one of claims 26~~29~~ – 28~~31~~ in the manufacture of a medicament for treating or preventing ~~a condition associated with~~ hyperuricemia in a subject in need thereof, wherein an effective amount of the medicament is to be administered to the subject.

31~~34~~. Use of the pharmaceutical composition of any one of claims 26 – 28 in the manufacture of a medicament for treating or preventing ~~The use of claim 33, wherein the condition is~~ gout, a recurrent gout attack, gouty arthritis, hypertension, ~~a cardiovascular disease, coronary heart disease, heart failure,~~ Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, chronic kidney disease, kidney stones, kidney failure, diabetic kidney disease, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof in a subject in need thereof.

32~~35~~. The use of claim 30~~33~~, wherein the condition is gout.

33~~36~~. The use of claim 30~~33~~, wherein the condition is chronic kidney disease.

~~37. The use of claim 33, wherein the condition is heart failure~~.